NK - ImmunityBio's Anktiva shows clinical benefit in mid-stage lung cancer study

Privately-held ImmunityBio which announced to merge with NantKwest ([[NK]] -3.3%) has announced data presentation from ongoing Phase 2b study evaluating Anktiva (N-803) in non-small cell lung cancer ((NSCLC)).Clinical benefit was demonstrated in a majority of the NSCLC patients, as measured by reduction of target lesion size and cessation of progression in the target lesion over time (with follow-up of up to 13 months).Clinical benefit was observed in patients who progressed on checkpoint inhibitors, on Anktiva combination therapy with checkpoint inhibitors, regardless of PD-L1 status or use of chemotherapy with checkpoint inhibitors.Combination regimen of Anktiva and checkpoint inhibitors was well tolerated, with low incidence of treatment-related severe adverse events in second- and third-line NSCLC patients.

For further details see:

ImmunityBio's Anktiva shows clinical benefit in mid-stage lung cancer study